Small Molecule Compounds
High Safety Profile
Demonstrates improved safety compared with existing therapies.
Thoroughly Researched
Comprehensively studied in accordance with human pharmaceutical standards, including activity, PK/PD, and toxicology.
Cost-Efficient
API supports large-scale manufacturing with stable and controllable costs.
Extensive Experience
Proven expertise in developing multiple dosage forms.
Comprehensive Protection
Robust intellectual property protection in place.
Strategic Partnerships & Companion Diagnostics
Existing mainstream medications are recommended for common pruritic skin diseases in dogs by both domestic and international clinical guidelines. AC001 aims to benchmark and surpass analogy preparations in terms of efficacy, safety, and cost-effectiveness, providing a highly effective, safe, and cost-efficient treatment option for the global canine pruritic skin disease market, meeting the growing health demands of pet owners worldwide.
Co-Creation Through Technological Integration
Amicure has established strategic collaborations with leading pharmaceutical companies domestically and internationally. We are applying patented human drug formulation technology platforms, along with successful experiences and achievements in pharmaceutical development of human drugs, to the field of veterinary drugs and formulations.
Companion Diagnostic Technology
AC001 represents a pioneering pet pruritus treatment solution that integrates an “innovative formulation” with a “companion diagnostic (Amicure Diagnostics)”. It aims to fill the gap in pet pruritus testing in the global market, enabling rapid and accurate detection of pet autoimmune disease indicators within a short time frame, achieving a personalized “integrated diagnosis and treatment” outcome.
New Chapter in Kinase Inhibition
Various diseases, including hematological disorders such as tumors, myelofibrosis, and thrombocytosis, as well as autoimmune diseases like vitiligo, psoriasis, atopic dermatitis, and rheumatoid arthritis, are associated with abnormal activation of the JAK-STAT pathway. JAK kinase inhibitors, as crucial targets for treating the aforementioned diseases, hold significant potential.
Focused on Signaling Pathways
Aberrant activation of the JAK-STAT pathway is closely associated with the onset and progression of multiple major diseases.
Covering Multiple Disease Types
Spanning a wide range of conditions, from cancers and hematologic disorders to autoimmune diseases such as vitiligo and psoriasis.
Focused on Signaling Pathways
Aberrant activation of the JAK-STAT pathway is closely associated with the onset and progression of multiple major diseases.
Contact Us
ir.marking@amicurebios.com
Room 1811, 18th Floor Hopewell Centre 23 Harbour Road, Wan Chai Hong Kong
Where Innovation Meets
Accelerating the Future of Pet Health Together